• Posted 16-Dec-2019

Novel stem cell products for clinical trials in Type 1 Diabetes

The ISLET project is a multi-center collaboration of leading European researchers that has been awarded 8 million euros from the Horizon 2020 funding programme for research and innovation in a 5-year period.

The project will develop advanced stem cell products ready for use in clinical trials in Type 1 Diabetes. The project will develop a manufacturing pipeline for stem cell-based products to treat patients with Type 1 Diabetes. In Type 1 Diabetes a patient’s immune system destroys the beta cells within the islets of Langerhans in the pancreas making a patient dependent on life-long delivery of insulin.

Based on in-house methods, ISLET will deliver a product composed of clusters of insulin-producing beta cells, derived from human pluripotent stem cells, ready to be used in phase 1 clinical trials.

For more information, click here.

Source: European Commission, Research and Innovation News (http://bit.ly/2EhF81Y)